MedImmune LLC

The FDA approved FluMist, a nasal spray influenza vaccine, for self- or caregiver-administration in individuals aged 2 through 49. FluMist, initially approved in 2003, is the first influenza vaccine not needing a healthcare provider for administration. It aims to offer greater convenience and accessibility for vaccination, crucial for preventing flu-related illnesses and complications. The vaccine, containing weakened live influenza virus strains, is available through a third-party online pharmacy for self- or caregiver-administration after a screening and eligibility assessment.

FDA approves first self- or caregiver-administered flu vaccine FluMist for individuals 2 through 49 years old. FluMist, sprayed into the nose, is the first influenza vaccine not needing a healthcare provider for administration, potentially increasing convenience and accessibility. It was initially approved in 2003 for ages 5 through 49 and expanded to include children 2 through 5 in 2007.

FDA approves FluMist for self- or caregiver-administration, the first influenza vaccine not needing a health care provider. FluMist, for individuals 2-49, prevents flu caused by virus subtypes A and B. It was initially approved in 2003 for ages 5-49 and expanded in 2007 to include 2-5-year-olds. The vaccine, sprayed into the nose, offers convenience and accessibility. Side effects include fever, runny nose, nasal congestion, and sore throat. FluMist will be available via third-party online pharmacies, with a caregiver administering it to those aged 2-17.

The FDA approved FluMist for self- or caregiver-administration, making it the first influenza vaccine not needing a health care provider. FluMist, for individuals 2 through 49, is sprayed into the nose and has been used safely since 2003. It aims to provide greater convenience and accessibility for flu prevention.